Mesh.i
Checkpoint
PubMed
Racine
Checkpoint
PubMed
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (PubMed)

Index « Mesh.i » - entrée « Immunologic Factors »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
Immunologic Deficiency Syndromes < Immunologic Factors < Immunologic Memory  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 80.
[0-20] [0 - 20][0 - 50][20-40]
Ident.Authors (with country if any)Title
000264 (2019) Sisi Cai ; Zhaodong Zhong ; Xiang Li [République populaire de Chine] ; Hong Xiang Wang [République populaire de Chine] ; Li Wang [République populaire de Chine] ; Min ZhangTreatment of multicentric Castleman disease through combination of tocilizumab, lenalidomide and glucocorticoids: Case report.
000270 (2019) Helen Hayward-Koennecke [Autriche] ; Markus Reindl [Autriche] ; Roland Martin [Autriche] ; Sven Schippling [Autriche]Tocilizumab treatment in severe recurrent anti-MOG-associated optic neuritis.
000281 (2019) G. Novi [Italie] ; M. Gastaldi [Italie] ; D. Franciotta [Italie] ; G. Pesce [Italie] ; L. Benedetti [Italie] ; A. Uccelli [Italie]Tocilizumab in MOG-antibody spectrum disorder: a case report.
000312 (2019) Yoshihito Shima [Japon]The benefits and prospects of interleukin-6 inhibitor on systemic sclerosis.
000371 (2019) Tomoyuki Mutoh [Japon] ; Tomonori Ishii [Japon] ; Tsuyoshi Shirai [Japon] ; Kanae Akita [Japon] ; Yukiko Kamogawa [Japon] ; Yoko Fujita [Japon] ; Hiroko Sato [Japon] ; Yuko Shirota [Japon] ; Hiroshi Fujii [Japon] ; Hideo Harigae [Japon]Refractory Takayasu arteritis successfully treated with rituximab: case-based review.
000413 (2019) Masayoshi Harigai [Japon] ; Michi Tsutsumino [Japon] ; Hideto Takada [Japon] ; Kenji Nagasaka [Japon]Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis.
000531 (2019) C. Diener [Allemagne] ; G. Horneff [Allemagne]Comparison of adverse events of biologicals for treatment of juvenile idiopathic arthritis: a systematic review.
000578 (2019) Ibrahim Khilfeh ; Eric Guyette [États-Unis] ; John Watkins [États-Unis] ; Dan Danielson [États-Unis] ; David Gross [États-Unis] ; Kai YeungAdherence, Persistence, and Expenditures for High-Cost Anti-Inflammatory Drugs in Rheumatoid Arthritis: An Exploratory Study.
000589 (2019) Tomohiro Koga [Japon] ; Remi Sumiyoshi [Japon] ; Atsushi Kawakami [Japon] ; Kazuyuki Yoshizaki [Japon]A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman's disease.
000631 (2018) Jin-Sun Jun [Corée du Sud] ; Soon-Tae Lee [Corée du Sud] ; Ryul Kim [Corée du Sud] ; Kon Chu [Corée du Sud] ; Sang Kun Lee [Corée du Sud]Tocilizumab treatment for new onset refractory status epilepticus.
000641 (2018) Rachel L. Randell [États-Unis] ; Ashley V. Adams [États-Unis] ; Heather Van Mater [États-Unis]Tocilizumab in Refractory Autoimmune Encephalitis: A Series of Pediatric Cases.
000651 (2018) Hiromichi Tamaki [Japon] ; Rula A. Hajj-Ali [États-Unis]Tocilizumab for Giant Cell Arteritis-A New Giant Step in an Old Disease.
000664 (2018) Yu Fujiwara [Japon] ; Kanae Ito [Japon] ; Akito Takamura [Japon] ; Kaoru Nagata [Japon]The first case of thrombocytopenia, anasarca, fever, renal impairment or reticulin fibrosis, and organomegaly (TAFRO) syndrome with unilateral adrenal necrosis: a case report.
000725 (2018) M. Guevara [États-Unis] ; C S Kollipara [États-Unis]Recent Advances in Giant Cell Arteritis.
000773 (2018) Alexander G S. Oldroyd [Royaume-Uni] ; Deborah P M. Symmons [Royaume-Uni] ; Jamie C. Sergeant [Royaume-Uni] ; Lianne Kearsley-Fleet [Royaume-Uni] ; Kath Watson [Royaume-Uni] ; Mark Lunt [Royaume-Uni] ; Kimme L. Hyrich [Royaume-Uni]Long-term persistence with rituximab in patients with rheumatoid arthritis.
000777 (2018) Damien Biotti [France] ; Fleur Lerebours [France] ; Fabrice Bonneville [France] ; Jonathan Ciron [France] ; Michel Clanet [France] ; David Brassat [France]Late-onset neutropenia and neurological relapse, during long-term rituximab therapy in myelin oligodendrocyte glycoprotein-antibody spectrum disorder.
000A07 (2017) Asami Masui-Ito [Japon] ; Ryuji Okamoto ; Kaoru Ikejiri ; Mika Fujimoto ; Muneyoshi Tanimura ; Shiro Nakamori ; Tomohiro Murata ; Eiji Ishikawa ; Norikazu Yamada ; Hiroshi Imai ; Masaaki ItoTocilizumab for uncontrollable systemic inflammatory response syndrome complicating adult-onset Still disease: Case report and review of literature.
000A19 (2017) Monika Stensen [Norvège]The use of biologics in pregnant patients with rheumatic disease.
000A52 (2017) Olafur Sveinsson [Suède] ; Mathias Granqvist [Suède] ; Yngve Forslin [Suède] ; Kaj Blennow [Suède] ; Henrik Zetterberg [Royaume-Uni] ; Fredrik Piehl [Suède]Successful combined targeting of B- and plasma cells in treatment refractory anti-NMDAR encephalitis.
000A80 (2017) Laurie S. Davis ; Andreas M. ReimoldResearch and therapeutics-traditional and emerging therapies in systemic lupus erythematosus.
000B53 (2017) Achille Marino [Italie] ; Sona Narula [États-Unis] ; Melissa A. Lerman [États-Unis]First Pediatric Patient With Neuromyelitis Optica and Sjögren Syndrome Successfully Treated With Tocilizumab.

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/PubMed/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Mesh.i -k "Immunologic Factors" 

HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/Mesh.i  \
                -Sk "Immunologic Factors" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    PubMed
   |étape=   Checkpoint
   |type=    indexItem
   |index=    Mesh.i
   |clé=    Immunologic Factors
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021